Fostera prrs

In this study we used three monovalent vaccines; inactivated M. hyopneumoniae bacterin (RespiSure‐One, Zoetis, Serial No. 185372), modified‐live PRRSV vaccine (Fostera PRRS, Zoetis, Serial No. SN163540/159469, Lot No. 169588), and PCV2 subunit vaccine (Ingelvac CircoFLEX, Boehringer Ingelheim Vetmedica, Serial No. 3091076A) which were prepared and administered according to the manufacturer's instruction. A trivalent M. hyopneumoniae‐PCV2‐PRRSV vaccine (Ingelvac 3FLEX vaccine, Boehringer Ingelheim Vetmedica; Ingelvac CircoFLEX, Serial No. 3091076A; Ingelvac MycoFLEX, Serial No 270472A; Ingelvac PRRS MLV, Serial No. 2451124B) was prepared according to manufacturer's mixing instructions and was also used.

Breeding sow farms were eligible for this study if they were a) diagnostic evidence to support the status of ‘PRRS stable’ according to the AASV guidelines, b) implementing routine vaccinations with a commercial PRRS MLV vaccine (PRRS Ingelvac MLV (Boehringer Ingelheim Vetmedica Inc., St Joseph, MO); PRRS Ingelvac ATP (Boehringer Ingelheim Vetmedica Inc., St Joseph, MO); or Fostera PRRS (Zoetis Inc., Parsippany-Troy Hills, NJ)), c) able to provide vaccination dates, and weekly production records required for this study, and d) not having clinical outbreaks of infectious diseases that may impact the parameters that were measured, including porcine epidemic diarrhea (PED).